Hospital Vall d'Hebron-ko ikertzaileekin lankidetzan egindako argitalpenak (69)

2024

  1. The incidence of HIV-2 infection in Spain is declining – a registry data analysis

    International Journal of Infectious Diseases, Vol. 146

2023

  1. Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions

    Journal of Clinical Virology, Vol. 167

  2. HTLV-1-associated myelopathy in Spain

    Journal of Clinical Virology, Vol. 169

  3. The slowdown of new infections by human retroviruses has reached a plateau in Spain

    Journal of Medical Virology, Vol. 95, Núm. 5

2022

  1. Late presentation of human T-lymphotropic virus type 1 infection in Spain reflects suboptimal testing strategies: on behalf of the Human T-lymphotropic Virus (HTLV) Spanish Network

    International Journal of Infectious Diseases, Vol. 122, pp. 970-975

2021

  1. Current epidemiological status of HIV-2 and HTLV-1 infection in Spain

    Medicina Clinica, Vol. 156, Núm. 6, pp. 290-296

  2. Short Communication: Impact of COVID-19 on Case Reporting for HTLV and HIV-2 in Spain

    AIDS Research and Human Retroviruses, Vol. 37, Núm. 8, pp. 610-612

2020

  1. Antiretroviral therapy for HIV-2 infection in non-endemic regions

    AIDS Reviews, Vol. 22, Núm. 1, pp. 44-56

2019

  1. Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain

    Journal of Antimicrobial Chemotherapy, Vol. 74, Núm. 5, pp. 1357-1362

  2. Clinical presentation of individuals with human T-cell leukemia virus type-1 infection in Spain

    Open Forum Infectious Diseases, Vol. 6, Núm. 2

  3. HIV co-infection in HTLV-1 carriers in Spain

    Virus Research, Vol. 266, pp. 48-51

  4. HIV-2 molecular epidemiology in Spain: 30 years since the first case

    VIRUS EVOLUTION

  5. Treatment outcome in dually HIV-1 and HIV-2 coinfected patients living in Spain

    AIDS, Vol. 33, Núm. 14, pp. 2167-2172

2017

  1. Antiretroviral treatment of HIV-2 infection

    Future Virology, Vol. 12, Núm. 8, pp. 461-472

  2. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 7, pp. 2083-2088

  3. HIV type 2 epidemic in Spain: Challenges and missing opportunities

    AIDS, Vol. 31, Núm. 10, pp. 1353-1364

  4. Human T-lymphotropic virus type 1 infection and disease in Spain

    AIDS, Vol. 31, Núm. 12, pp. 1653-1663

  5. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

2015

  1. Dolutegravir for the treatment of HIV-2 infection

    Journal of Clinical Virology, Vol. 64, pp. 12-15